Cornerstone Pharmaceutical-B (02616) is included in the list of securities included in the Hong Kong Stock Exchange

According to the Zhitong Finance App, Cornerstone Pharmaceutical-B (02616) announced that shares issued by the Company and listed on the Hong Kong Stock Exchange Limited were included in the Hong Kong Stock Exchange List, which will take effect from September 7, 2026.

Dr. Yang Jianxin, CEO, R&D President and Executive Director of Cornerstone Pharmaceuticals, said, “This successful inclusion in the Hong Kong Stock Exchange Securities List fully demonstrates the capital market's high recognition of the company's innovative strength and long-term development potential. This inclusion is expected to further enrich the company's investor structure and enhance the liquidity of the company's shares in the secondary market. Looking forward to the future, Cornerstone Pharmaceuticals will continue to promote the global development of core assets, consolidate core competitiveness through efficient pipeline promotion and commercialization layout, and create long-term and sustainable value returns for investors.”

Cornerstone Pharmaceuticals has always focused on unmet global clinical needs and adheres to a differentiated and innovative layout. The global phase I/II clinical trial of the PD-1/VEGF/CTLA‑4 tri-specific antibody CS2009, which is our core asset, is progressing efficiently, and it is expected that the first batch of global phase III registered clinical trials will begin before the end of 2026. A global phase I clinical trial of the company's self-developed EGFR/HER3 bispecific ADC CS5007 has also started and will be carried out simultaneously in China and Australia. In addition, several next-generation ADC projects, as well as dual antibody programs in the field of immunity and inflammation, are about to enter the New Drug Clinical Trial Application (IND) application stage.